Aqueous cytokine and growth factor levels indicate response to ranibizumab for diabetic macular oedema

Abstract

Response to ranibizumab treatment for DME appears to be associated with aqueous concentrations of VEGFR1 family and certain inflammatory cytokines, but not with clinical parameters.

<p>Cytokine and Chemokine Profile Changes in Patients After Intravitreal Conbercept Injection for Diabetic Macular Edema</p>

“…The selection of cytokines for detection was based on previous studies. [16][17][18][19] The following cytokines were analysed: platelet-derived growth factor bb (PDGFF-bb), interleukin-1 beta (IL-1β), interleukin-1 receptor antagonist (IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15 and IL-17, eotaxin, basic fibroblast growth factor (FGF basic), granulocyte colony stimulating factor (G-CSF), granulocytemacrophage colony-stimulating factor (GM-CSF), interferon…”

Cytokines and Growth Factors as Predictors of Response to Medical Treatment in Diabetic Macular Edema

“…As previously mentioned, the efficacy of DME treatment may be related to aqueous humor concentration of some cytokines. Therefore, it is possible that the baseline levels of these molecules could be used to predict response to therapy (Shimura et al, 2017;Hillier et al, 2018;Kwon and Jee, 2018).…”

“…Although the great majority of patients improved DME after anti-VEGF treatment, some patients fail to respond to this therapy. In order to identify which patients will not respond to anti-VEGF injections and that will benefit of treatment with corticosteroids, recent studies start to evaluate the hypothesis of cytokine and growth factors as predictors of response to anti-VEGF or corticosteroids intravitreal injections (Shimura et al, 2017;Hillier et al, 2018;Kwon and Jee, 2018).…”

“…Besides, the total number of injections necessary to achieve and maintain averaged 3.2 ± 1.3 during the course of 6 months (Shimura et al, 2017). VEGF, PlGF, VEGFR1 and 2, MCP-1, ICAM-1, PDGF-AA, IL-6, IL-8, and IP-10 were measured.…”

“…No significant differences in BCVA and CMT among the 6 groups were observed at baseline, but significant differences were detected after 6 months. When comparing the group that received one single injection (good responders) with the group that received six injections (poor responders), significant differences in baseline VEGF, sVEGFR1, PlGF, MCP-1, ICAM-1, IP-10, and IL-6 were observed (Shimura et al, 2017).…”